Edition:
United States

Chiasma Inc (CHMA.OQ)

CHMA.OQ on NASDAQ Stock Exchange Global Select Market

1.55USD
3:59pm EST
Change (% chg)

$-0.05 (-3.12%)
Prev Close
$1.60
Open
$1.60
Day's High
$1.60
Day's Low
$1.55
Volume
395
Avg. Vol
9,867
52-wk High
$2.95
52-wk Low
$1.25

Chart for

About

Chiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial... (more)

Overall

Beta: --
Market Cap(Mil.): $39.01
Shares Outstanding(Mil.): 24.38
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 30.98 16.31
EPS (TTM): -- -- --
ROI: -- 14.12 35.74
ROE: -- 15.72 17.71

BRIEF-Chiasma Announces Expected Year-End 2017 Cash And Investments Balance Of About $67 Mln

* CHIASMA INC - ANNOUNCES EXPECTED YEAR-END 2017 CASH AND INVESTMENTS BALANCE OF APPROXIMATELY $67 MILLION

Jan 08 2018

BRIEF-Chiasma Q3 loss per share $0.28

* Chiasma Inc - ‍ cash, cash equivalents & marketable securities as of Sept 30, 2017 were $73.2 million, compared with $93.0 million as of December 31, 2016​ Source text for Eikon: Further company coverage:

Nov 09 2017

BRIEF-Chiasma announces first patient is randomized in phase 3 trial of Octreotide capsules in patients with acromegaly

* Chiasma announces first patient is randomized in phase 3 chiasma optimal clinical trial of Octreotide capsules in patients with acromegaly

Sep 27 2017

Earnings vs. Estimates